May 4, 2021 6 min read
This story originally appeared on StockMarket
Healthcare stocks have cracked in the stock market. Regardless of what happens elsewhere in the economy, the healthcare industry is likely to continue to work to improve our quality of life. If so, it would make sense for investors to turn to top healthcare stocks now to buy them. In the past year, the health sector in particular was largely in the limelight. Thanks to the sudden need for a coronavirus vaccine, countless people are knowing more about drug regulation processes.
Additionally, the broader market for tech investors hasn’t been too friendly lately. Given the recent volatility in technology stocks, investors would likely bet on more defensive games. This is when world-class health stocks come into play, most of which withstand what is happening in the world for the most part.
For example, biotech company Brooklyn Immunotherapeutics Inc. (NYSE: BTX) expects clinical-stage growth of nearly 2,000% last month. This would be owed to the right to an exclusive license that the company would like to use for the development of mRNA gene editing compounds and cell therapies. At the same time, vaccine companies like Moderna (NASDAQ: MRNA) and Johnson & Johnson (NYSE: JNJ) continue to hold. If anything, the ongoing battle against the coronavirus is still one that investors seem to be betting on. If you want all of these to add some top healthcare stocks to your portfolio, here are four to consider in the stock market today.
First, Precipio is brand new on the stock market now. The company launches its rapid COVID-19 antibody test for sale on the world’s largest e-commerce Amazon (NASDAQ: AMZN). What’s more impressive is that this was the first U.S.-based test to receive emergency site approval from the U.S. Food and Drug Administration (FDA). The development sparked a sharp move in PRPO stock as it gained more than 170% in intraday trading on Monday. And it continued to rise 27% on today’s opening bell.
“We are very excited to be working with our partner Nirmidas to run this important rapid test on the largest retail platform in the world. We look forward to working with other retail outlets as well as Nirmidas to develop this product for home use upon receipt of appropriate FDA approval. “- Ilan Danieli, CEO of Precipio.
Aside from the COVID-19 antibody test kits, the company’s main interest is actually in its diagnostic platform. In particular, Precipio developed the HemeScreen technology to prevent misdiagnosis of certain types of cancer. In fact, earlier this year the company signed an agreement with two of the largest oncology practices in the United States. With so many exciting developments going on around the company today, would you chase PRPO shares on the stock market?
[Read More] Best Tech Stocks You Can Buy Right Now? 4 to see
Next we have biopharmaceutical specialist Ocugen in the clinical stage. The company was focused on developing cures for blindness diseases, but the coronavirus pandemic outbreak has shifted the company’s focus. OCGN stock investors are now involved in a company that competes with other COVID-19 vaccine manufacturers. And if you had placed your bets on OCGN stocks in early December, you would have gained at least 4,500% over that period. The company’s shares received another catalyst after the company released promising data from its vaccine candidate.
The company has worked endlessly to advance the development of the COVID-19 vaccine candidate Covaxin together with partner Bharat Biotech. Indian Council of Medical Research (ICMR) researchers believe its vaccine candidate could protect against multiple strains of coronavirus.
“Covaxin continues to show strong results in all studies conducted to date,” said Dr. Shankar Musunuri, co-founder and CEO of Ocugen, in a press release. “We continue to believe that this vaccine will be an important tool to add to our national arsenal to fight this pandemic.” Should the company manage to get regulatory approval, I won’t be surprised if OCGN stock breaks out again.
When making a list of healthcare stocks to buy, Intuitive Surgical is difficult not to list. The company is a leader in robotic surgery. To date, the company has helped tens of thousands of surgeons perform 7 million procedures worldwide. By using precise and efficient robots, the company is characterized by minimally invasive care. Da Vinci’s surgical system will help improve the surgeon’s skills. It offers precision, less bleeding and faster recovery times.
Following the company’s first quarter earnings, revenue increased 18% year over year to $ 1.29 billion. Also noteworthy was the improvement in Intuitive Surgical’s non-GAAP results. The company reported non-GAAP net income of $ 427 million compared to $ 323 million for the same period last year. Put simply, the company seems to be shooting at all cylinders.
Investors should also watch Intuitive Surgical expand in Asia and other key markets. The potential for robotic surgical devices remains enormous, and Intuitive Surgical is at the forefront of this innovative wave. With that in mind, would you invest in ISRG shares?
[Read More] Best stocks for 2021? 4 Ecommerce Stocks To Know
Last but not least, the coronavirus vaccine candidate Novavax is a worth seeing health stock. This is because the company is about to apply for emergency clearance for its COVID-19 vaccine candidate. The company’s two-dose vaccine showed 96% effectiveness against the novel coronavirus. It also appears to have the ability to handle today’s COVID-19 variants to some extent. In addition, Novavax reported that the vaccine was 100% effective in preventing serious side effects that might require hospitalization.
Not sure if you can remember, and Operation Warp Speed has agreed to pay Novavax $ 1.6 billion to pre-order 100 million cans. Without going into too much financial detail, Novavax contracts could be worth over $ 6 billion at a dose of $ 16 per dose. Should the company’s vaccine get FDA approval, it would be a huge, multi-billion dollar product for the company.
Another exciting development is that the company is also trying to combine both its COVID-19 vaccine and its flu vaccine in a single shot. This certainly sounds more attractive compared to other COVID-19 vaccines. Clinical studies are expected to start in mid-2021. While these developments don’t materialize, the company is developing yet another potential revenue generator for its flu vaccine, which may be ready for the market in a few years. Given all of this, are you considering investing in NVAX stocks?